Skip to main content
Premium Trial:

Request an Annual Quote

Invitae Exome Reanalysis

Invitae has begun offering customers of its exome sequencing service routine case-level reanalysis of their results every six months for a minimum of three years. This will ensure that patients' results are up to date based on the latest variant classification research. The reanalysis will be conducted by the company's team of genetics experts, who will utilize an artificial intelligence-powered diagnosis engine that Invitae garnered with the acqusition of Belgian firm Diploid, and a gene-phenotype database.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.